In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III)

Objectives

1. To measure the Day 28, PCR corrected cure rates of artemether-lumefantrine (Coartem) and Amodiaquine-artesunate (Coarsucam).
2. To evaluate the incidence of adverse events
3. PCR uncorrected Day 28 efficacy of AL and AQ-AS
4. Evaluate the presence of Molecular Markers associated with sub-optimum responses to ACTs